GSK's Shingrix has only tapped part of a huge market: exec by Eric Sagonowsky Thursday, January 16, 2020 GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.
GSK's booming Shingrix wins nod to tackle China by Angus Liu Wednesday, May 22, 2019 GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.
GSK's Shingrix beats expectations again in Q2 by Eric Sagonowsky Friday, July 27, 2018 GSK's shingles shot Shingrix has routinely beaten expectations since its U.S. rollout, and its second-quarter performance was no different.
Doctors worry Shingrix side effects will put patients off their 2nd dose by Eric Sagonowsky Wednesday, June 20, 2018 Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors.
Glaxo's Shingrix should chip in $600M this year, execs say by Eric Sagonowsky Monday, April 30, 2018 GSK's Shingrix carried high expectations, but it turns out that even those ambitious projections weren't high enough.
7. GlaxoSmithKline by Eric Sagonowsky It was something of a rebuilding year for GlaxoSmithKline in 2017. It was CEO Emma Walmsley's first at the helm, and the company subsequently won three blockbuster approvals for shingles vaccine Shingrix, COPD med Trelegy and HIV drug Juluca.
GSK’s Shingrix crowds out Merck in U.S. shingles vax market by Angus Liu Wednesday, April 11, 2018 GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.
GlaxoSmithKline's Shingrix recommended in Europe by Eric Sagonowsky Friday, January 26, 2018 After picking up key regulatory nods in the U.S., GlaxoSmithKline’s Shingrix is well on its way to expanding its reach into Europe.
CDC panel recommends GSK's Shingrix over older Merck shot by Eric Sagonowsky Wednesday, October 25, 2017 The CDC committee in charge of vaccination policy in the U.S. endorsed GlaxoSmithKline's Shingrix over the older shot, Merck's Zostavax.
